Revolution Medicines, Inc. RVMD
We take great care to ensure that the data presented and summarized in this overview for Revolution Medicines, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RVMD
View all-
Vanguard Group Inc Valley Forge, PA15.7MShares$1.06 Billion0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA14.6MShares$991 Million2.96% of portfolio
-
Black Rock Inc. New York, NY13.4MShares$908 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X011.4MShares$769 Million0.26% of portfolio
-
Wellington Management Group LLP Boston, MA9.81MShares$665 Million0.08% of portfolio
-
Baker Bros. Advisors LP New York, NY9.46MShares$641 Million3.6% of portfolio
-
Nextech Invest, Ltd. Zurich, V87.6MShares$515 Million54.03% of portfolio
-
Nextech Invest Ag7.6MShares$515 Million61.97% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY6.22MShares$422 Million9.36% of portfolio
-
Bellevue Group Ag Kuesnacht, V85.57MShares$378 Million5.57% of portfolio
Latest Institutional Activity in RVMD
Top Purchases
Top Sells
About RVMD
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Insider Transactions at RVMD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 25
2025
|
Mark A Goldsmith |
SELL
Open market or private sale
|
Indirect |
6,000
-4.26%
|
$450,000
$75.0 P/Share
|
|
Nov 25
2025
|
Mark A Goldsmith |
SELL
Open market or private sale
|
Direct |
60,000
-19.49%
|
$4,500,000
$75.08 P/Share
|
|
Nov 25
2025
|
Mark A Goldsmith |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+16.31%
|
$240,000
$4.09 P/Share
|
|
Nov 25
2025
|
Jack Anders Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,418
-4.65%
|
$400,932
$74.0 P/Share
|
|
Nov 25
2025
|
Jack Anders Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,418
+4.45%
|
$92,106
$17.0 P/Share
|
|
Nov 18
2025
|
Jeff Cislini General Counsel |
SELL
Open market or private sale
|
Direct |
13,388
-20.98%
|
$937,160
$70.14 P/Share
|
|
Nov 18
2025
|
Jeff Cislini General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
13,388
+17.34%
|
$562,296
$42.45 P/Share
|
|
Nov 18
2025
|
Mark A Goldsmith |
SELL
Open market or private sale
|
Direct |
20,000
-7.47%
|
$1,400,000
$70.38 P/Share
|
|
Nov 18
2025
|
Mark A Goldsmith |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+6.95%
|
$80,000
$4.09 P/Share
|
|
Nov 12
2025
|
Mark A Goldsmith |
SELL
Open market or private sale
|
Direct |
20,000
-7.47%
|
$1,300,000
$65.07 P/Share
|
|
Nov 12
2025
|
Mark A Goldsmith |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+6.95%
|
$80,000
$4.09 P/Share
|
|
Nov 12
2025
|
Mark A Goldsmith |
BUY
Bona fide gift
|
Indirect |
100,000
+44.68%
|
-
|
|
Nov 12
2025
|
Mark A Goldsmith |
SELL
Bona fide gift
|
Direct |
100,000
-15.58%
|
-
|
|
Nov 11
2025
|
Jack Anders Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-8.26%
|
$640,000
$64.0 P/Share
|
|
Nov 11
2025
|
Jack Anders Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+7.63%
|
$170,000
$17.0 P/Share
|
|
Nov 07
2025
|
Mark A Goldsmith |
SELL
Open market or private sale
|
Direct |
30,000
-7.94%
|
$1,800,000
$60.31 P/Share
|
|
Nov 07
2025
|
Mark A Goldsmith |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+3.76%
|
$60,000
$2.61 P/Share
|
|
Oct 17
2025
|
Mark A Goldsmith |
SELL
Open market or private sale
|
Direct |
10,000
-2.16%
|
$550,000
$55.0 P/Share
|
|
Oct 17
2025
|
Mark A Goldsmith |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.12%
|
$10,000
$1.12 P/Share
|
|
Oct 17
2025
|
Jeff Cislini General Counsel |
SELL
Open market or private sale
|
Direct |
12,000
-19.22%
|
$660,000
$55.0 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 246K shares |
|---|---|
| Open market or private purchase | 1.3M shares |
| Bona fide gift | 100K shares |
| Exercise of conversion of derivative security | 419K shares |
| Bona fide gift | 103K shares |
|---|---|
| Open market or private sale | 469K shares |
| Grant, award, or other acquisition | 20.8K shares |